

JAN 21 2011

15 510(k) SUMMARY

15.1 General Information

Applicant: Biosense Webster, Inc.
3333 Diamond Canyon Road
Diamond Bar, CA 91765
USA
Phone: 909-839-8597
Fax: 909-839-8804

Date: December 22, 2010.

Contact Person: Wayne R. Hohman
Project Manager Regulatory Affairs

Trade/Proprietary Device Name: CARTO[®] 3 V2.0 EP Navigation System and Accessories
Manufacturing Part Numbers: FG-5400-00 (with standard location pad)
FG-5600-00 (with RMT location pad)

Common Device Name: Cardiac mapping system

Classification Name: Programmable diagnostic computer
Class II, 21 CFR 870.1425 Product Code DQK

Predicate Devices: CARTO[®] 3 V1.05 EP Navigation System and
Accessories (519(k) K093455)
Ensite Velocity[™] System (510(k) K101328)

Manufacturing Facilities: Biosense Webster (Israel) Ltd.
a Johnson & Johnson Company
4 Hatnufa Street, POB 275
Yokneam 20692
Israel

15.2 Substantial Equivalence

The CARTO® 3 EP Navigation System, Version 2.0, is substantially equivalent to the legally marketed CARTO® 3 EP Navigation System, Version 1.05, and a second predicate device as shown in the Table below:

Predicate Devices for CARTO® 3 EP Navigation System, Version 2.0		
Submission Name	510(k) Number	Equivalence Criteria
CARTO® 3 V1.05 EP Navigation System	K093455	FDA cleared version of CARTO®3 EP Navigation System prior to Version 2.0.
Ensite Velocity™ System	K101328	St. Jude Medical device

15.3 Description of Device

The CARTO® 3 V2.0 EP Navigation System is a catheter-based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheter and reference device. The system allows real-time display of electrograms and cardiac maps based on the received intra cardiac signals from the catheters in a number of different formats. The acquired patient signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO® 3 V2.0 System uses two distinct types of location technology – magnetic sensor technology and Advanced Catheter Location (ACL) technology.

15.4 Indications for Use

The Indications for Use for the modified device are identical to the predicate device:

The CARTO® 3 V2.0 System is intended for catheter-based atrial and ventricular mapping. The mapping system allows real-time display of cardiac maps in a number of different formats. Maps may be displayed as anatomical maps, cardiac electrical activation maps, cardiac electrical propagation maps, cardiac electrical potential maps, impedance maps, cardiac chamber geometry maps and ECG fragmentation maps. The acquired patient signals, including body surface ECG and intracardiac electrograms may also be displayed in real time on the System's display screen. The CARTO® 3 V2.0 System is also intended to support EP procedures, maintaining CARTO® System capabilities, in the presence of a high metallic environment and magnetic field strengths up to 0.1 T and provide a data communication channel to the Stereotaxis Niobe® Catheter Navigation System. The CARTO® 3 V2.0 System includes CARTOMERGE® Plus functionality to import, register and merge CT or MRI structural images with CARTO® map's physiological information and real time catheter navigation. The system

includes the Fast Anatomical Mapping (FAM) functionality that allows for the quick creation of cardiac anatomical volumes using catheters with magnetic location sensors. The system's CARTOSOUND™ image integration functionality enables integration of intracardiac echo (ICE) to enable visualization of 3D combined maps. In addition to the use of specialized navigation catheters with magnetic location sensors, the system is also intended for use with conventional, non-navigational, electrophysiology catheters without magnetic location sensors.

15.5 Summary of Non-clinical Performance Testing

The CARTO® 3 V2.0 EP Navigation System underwent extensive Bench and Animal Testing to verify the modified features and to demonstrate with regression testing that the new features did not negatively affect existing features. The CARTO® 3 V2.0 EP Navigation System passed all tests in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.

15.6 Conclusions

The Bench and Animal Non-clinical Testing demonstrated that the CARTO® 3 V2.0 EP Navigation System is as safe, as effective, and performs as well as or better than the predicate devices. This testing program supports the determination of substantial equivalence to the predicate devices.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

Biosense Webster, Inc.
c/o Mr. Wayne R. Hohman
Project Manager Regulatory Affairs
3333 Diamond Canyon Road
Diamond Bar, CA 91765

JAN 21 2011

Re: K103746
CARTO® 3 V2.0 EP Navigation System
Regulatory Number: 21 CFR 870.1425
Regulation Name: Programmable Diagnostic Computer
Regulatory Class: II (two)
Product Code: 74 DQK
Dated: December 22, 2010
Received: December 23, 2010

Dear Mr. Hohman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. Wayne R. Hohman

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,


for Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

5 INDICATIONS FOR USE

510(k) No (if known): _____

Device Name: CARTO® 3 V2.0 EP Navigation System

Indications for Use:


The CARTO® 3 V2.0 System is intended for catheter-based atrial and ventricular mapping. The mapping system allows real-time display of cardiac maps in a number of different formats. Maps may be displayed as anatomical maps, cardiac electrical activation maps, cardiac electrical propagation maps, cardiac electrical potential maps, impedance maps, cardiac chamber geometry maps and ECG fragmentation maps. The acquired patient signals, including body surface ECG and intracardiac electrograms may also be displayed in real time on the System's display screen. The CARTO® 3 2.0 System is also intended to support EP procedures, maintaining CARTO® System capabilities, in the presence of a high metallic environment and magnetic field strengths up to 0.1 T and provide a data communication channel to the Stereotaxis Niobe® Catheter Navigation System. The CARTO® 3 V2.0 System includes CARTOMERGE® PLUS functionality to import, register and merge CT or MRI structural images with CARTO® map's physiological information and real time catheter navigation. The system includes the Fast Anatomical Mapping (FAM) functionality that allows for the quick creation of cardiac anatomical volumes using catheters with magnetic location sensors. The system's CARTOSOUND™ image integration functionality enables integration of intracardiac echo (ICE) to enable visualization of 3D combined maps. In addition to the use of specialized navigation catheters with magnetic location sensors, the system is also intended for use with conventional, non-navigational, electrophysiology catheters without magnetic location sensors.

Prescription Use ✓
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)



Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Cardiovascular Devices

Page 1 of 1

510(k) Number K103746